文献速递淋巴瘤造血干细胞移植与细胞治疗血栓与止血

T-ICAHT:CAR T细胞治疗后血小板减少的分级与预后影响

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
PubMed 文献 · Blood · 2025-01-01

这项多中心观察性研究在744例接受商业CD19 CAR-T治疗的B细胞非霍奇金淋巴瘤患者中系统分析血小板减少模式,建立基于深度、持续时间和发生时间的T-ICAHT分级体系。43%患者发生任何级别早期T-ICAHT(第0-30天),23%发生严重(≥3级)表现;晚期T-ICAHT(第31-100天)见于42%(≥3级13%)。T-ICAHT分级与总生存呈负相关,并在3个外部队列共599例儿童和成人患者中得到验证。

要点

  • 核心NHL数据集中43%发生任何级别早期T-ICAHT,23%发生≥3级严重表现
  • 晚期T-ICAHT(第31-100天)见于42%,其中≥3级占13%
  • T-ICAHT分级越高,血小板和红细胞输注负担及出血事件越多,总生存越差

核心结论

  • T-ICAHT分级与总生存呈负相关,支持将T-ICAHT整合入ICAHT框架以标准化CAR-T受者血小板减少分级。

研究设计与样本

  • 多中心观察性研究,系统分析744例接受商业CD19 CAR-T治疗的B细胞非霍奇金淋巴瘤患者的血小板减少模式。
  • 基于血小板减少的深度、持续时间和发生时间建立T-ICAHT分级体系,阈值与N-ICAHT密切对齐。
  • 在3个外部队列共599例儿童和成人患者(NHL、多发性骨髓瘤和B细胞急性淋巴细胞白血病)中验证T-ICAHT的临床和预后效用。

主要发现

  • 核心NHL数据集中43%患者发生任何级别早期T-ICAHT(第0-30天),23%发生严重(≥3级)表现。
  • 晚期T-ICAHT(第31-100天)见于42%患者,其中≥3级占13%。
  • T-ICAHT与N-ICAHT分级显示一定相关性,但存在相当程度的不一致。
  • 多变量分析中,桥接治疗、体能状态差和高HEMATOTOX评分与严重早期T-ICAHT风险增加相关。
  • T-ICAHT分级越高,血小板和红细胞输注负担及出血事件越多;界标2年总生存估计从0级67%降至1-2级48%和≥3级35%。

关键数值与推荐

  • T-ICAHT分级阈值与N-ICAHT密切对齐,基于血小板减少的深度、持续时间和发生时间。
  • 早期T-ICAHT定义为第0-30天,晚期T-ICAHT定义为第31-100天。
  • 核心NHL数据集中任何级别早期T-ICAHT发生率为43%,严重(≥3级)为23%;晚期T-ICAHT发生率为42%,≥3级为13%。
  • 界标2年总生存估计:0级67%,1-2级48%,≥3级35%。

临床怎么用

  • 作者认为这些发现支持将T-ICAHT整合入ICAHT框架,以标准化CAR-T受者的血小板减少分级。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune effector cell-associated hematotoxicity (ICAHT) was recently introduced as a distinct toxicity category of chimeric antigen receptor (CAR) T-cell (CAR-T) therapy. Although a grading system based solely on neutrophil counts was proposed (hereafter termed N-ICAHT), the prevalence and prognostic impact of thrombocytopenia remain poorly defined. In this multicenter observational study, we systematically examined patterns of thrombocytopenia in 744 patients treated with commercial CD19 CAR-T for B-cell non-Hodgkin lymphoma (B-NHL). We developed a grading system termed T-ICAHT, with thresholds that closely aligned with N-ICAHT, based on depth, duration, and timing of thrombocytopenia. In the core NHL data set, 43% of patients developed any-grade early T-ICAHT (days 0-30), with 23% developing severe (grade ≥3) manifestations. Late T-ICAHT (days 31-100) was observed in 42% (grade ≥3, 13%). Although T-ICAHT and N-ICAHT gradings showed some correlation, considerable discordance was noted. On multivariate analysis, bridging therapy, poor performance status, and high HEMATOTOX scores were associated with increased risk of severe early T-ICAHT. Patients with higher T-ICAHT grades showed increased platelet and red blood cell transfusion burden and more bleeding events. T-ICAHT grades were inversely associated with overall survival (OS), with landmarked 2-year estimates ranging from 67% (grade 0) to 48% (grade 1-2) and 35% (grade ≥3). In multivariable Cox regression analysis, the independent prognostic capacity of T-ICAHT for OS was confirmed. Finally, we validated T-ICAHT's clinical and prognostic utility in 3 external cohorts spanning an additional 599 pediatric and adult patients (NHL, multiple myeloma, and B-cell acute lymphoblastic leukemia), confirming its broad applicability. These findings support integrating T-ICAHT into the ICAHT framework to standardize thrombocytopenia grading in CAR-T recipients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rejeski K, Sanz J, Fei T, et al. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025. PMID: 40258181. doi:10.1182/blood.2025028833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。